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ABSTRACT
Wedescribeanewmethodfortheassayofsequence-
specific DNA-binding proteins in this paper. In this
method, the sensitive fluorescence resonance ene-
rgy transfer (FRET) technology is combined with the
commonDNAfootprintingassayinordertodevelopa
simple, rapid and high-throughput approach for
quantitatively detecting the sequence-specific DNA-
binding proteins. We named this method as exonuc-
leaseIII(ExoIII)protectionassaywithFRETprobe.The
FRET probe used in this assay was a duplex DNA
which was designed to contain one FRET pair in the
center and two flanking protein-binding sites. During
protein detection, if a target protein exists, it will bind
to the two protein-binding sites of the FRET probe
and thus protect the FRET pair from ExoIII digestion,
resulting in high FRET. However, if the target protein
doesnotexist,theFRETpaironthenakedFRETprobe
will be degraded by ExoIII, resulting in low FRET.
Three kinds of recombinant transcription factors
including NF-kB, SP1 and p50, and the target protein
of NF-kB in HeLa cell nuclear extracts, were success-
fully detected by the assay. This assay can be ext-
ensively used in biomedical research targeted at
DNA-binding proteins.
INTRODUCTION
Thesequence-speciﬁcDNA-bindingproteinsplaycriticalroles
in many cellular processes, including gene transcription regu-
lation (1), DNA replication (2), recombination (3), repair and
restriction (4). Among the various sequence-speciﬁc DNA-
binding proteins, those that are directly involved in the regu-
lation of gene transcription, e.g. DNA-binding transcription
factors, attract increasing interest because they play pivotal
roles in the pathways and networks of gene expression regu-
lation, and become potential targets in medical diagnosis and
drug development (5). For example,NF-kB (6), a transcription
factor that is involved in the regulation of a large number of
genes and closely related to multiple diseases, has already
become an important and popular target for drug develop-
ment (7). The research and development of sequence-
speciﬁc DNA-binding proteins attracts fast-growing attention
in genomics, proteomics and biomedicine. Therefore, there is
a need for robust methods to detect the presence of
these proteinsand monitortheir DNA-binding activities. How-
ever, the most common methods for detecting the sequence-
speciﬁc DNA-binding proteins including gel-shift assays (8)
and DNA footprinting assays (9,10) are laborious, radioactive
and time-consuming, which hinder them from more extensive
applications. In addition, both assays depend on gel electro-
phoresis, making them unadaptable to high-throughput
technology.
Fluorescence-based methods have been exploited for the
detection of sequence-speciﬁc DNA-binding proteins (11–14).
Fluorescence resonance energy transfer (FRET) was found to
be a powerful technique for the detection of biological inter-
actions (13,14). The FRET technique describes the transfer of
excitation energy from a donor ﬂuorophore to an acceptor
chromophore when the two dye molecules are separated by
<100 s and an overlap occurs between the donor emission and
acceptor absorption spectra (15). Two strategies using the
FRET technology have already been successfully applied to
the detection of DNA–protein interactions (13,14). In the ﬁrst
strategy, the DNA is labeled with one ﬂuorochrome and the
proteinwith another ﬂuorochrome. FRET was produced due to
the proximity between the DNA and the protein in the protein–
DNA complex (13). In the other strategy, known as the
molecular beacon assay, the DNA is labeled with two ﬂuoro-
chromes, each appearing in one duplex DNA of the two half
sites ofa DNA-binding protein. FRET was producedduetothe
protein-driven annealing of the two half sites (14). However,
the complicated procedures in labeling the protein with ﬂuore-
scence or in designing the proper half-sited DNA molecular
beacon may suppress their applications. Therefore, there is
still a need for the development of new methods based on
the superiority of FRET for detecting the sequence-speciﬁc
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We have been working on developing double-stranded
DNA microarray-based methods for this purpose (16).
However, we found that it was difﬁcult to analyze DNA-
binding proteins in sensitive and high-throughput format
using the double-stranded DNA microarray, although it was
helpful in studying DNA-binding activities of a protein to
multiple DNA targets (17). Based on our previous studies
using molecular beacons for detecting DNA mutations (18),
we introduced the sensitive FRET technology to the common
exonuclease III (ExoIII) footprinting assay to develop a new,
general, inexpensive FRET-based approach for assaying
sequence-speciﬁc DNA-binding proteins. This method allows
simple, rapid and high-throughput detection of the sequence-
speciﬁc DNA-binding proteins, and can be extensively used in
biomedical research targeted at DNA-binding proteins.
MATERIALS AND METHODS
FRET probes
Oligonucleotides were synthesized using the standard
phosphoramidate chemistry and were puriﬁed by HPLC
(BIOASIA, Shanghai). The following oligonucleotides were
synthesized for the NF-kB FRET probe (NF-kB probe):
5
0
-AGTTGAGGGGACTTTCCCAACTAGGAAFTCTACCT-
GGGGACTTTCCCAGGC-3
0
and 3
0
-TCAACTC CCCTGAAA-
GGGTTGATCCTDAAGATGGACCCCTGAAAGGGTCCG-5
0
(F, dT-FAM; D, dT-Dabcyl). The oligonucleotides used
for the SP1 FRET probe (SP1 probe) were: 5
0
-ATTCGA-
TCGGGGCGGGGCGAAAGCGA AFTCGATTCTCGGG-
GCGGGGCGTCG-3
0
and 3
0
-TAAGCTAGCCCCGCCCC-
GCTTTCGCTDAAGCTA AGAGCCCCGCCCCGCAGC-5
0
(F, dT-FAM; D, dT-Dabcyl). The oligonucleotides used for
the p53 FRET probe (p53 probe) were: 5
0
-GTCACAGACATG-
CCTAGACATGCCTTAACTAGGAAF/JTCTACCTCAGAC-
ATGCCTAGA CATGCCTTGCAG-3
0
and 3
0
-CAGTGTCTG-
TACGGATCTGTACGGAATTGATCCTDAAGATGGAGTC-
TGTACGGATCTGTACGGAACGTC-5
0
(F, dT-FAM; J,
dT-JOE; D, dT-Dabcyl). The italic sequence represents
the protein-binding sites. FAM is 6-carboxyﬂuorescein with
a maximum excitation wavelength of 494 nm and a maximum
emission wavelength of 520 nm; JOE is 6-carboxy-
4
0
,5
0
-dichloro-2
0
,7
0
-dimethoxyﬂuorescein with a maximum
excitation wavelength of 520 nm and a maximum emission
wavelength of 548 nm; Dabcyl is 4-(4
0
-dimethylamino-
phenylazo) benzoic acid with an absorbance wavelength of
453 nm and no ﬂuorescence emission. To obtain FRET probes
of duplex DNA, FAM or JOE-labeled donor oligonucleotides
and Dabcyl-labeled acceptor oligonucleotides were mixed in
the same molar ratios at the ﬁnal concentration of 50 mMi n
100 ml of 10 mM Tris–HCl (pH 8.0), 100 mM NaCl and 1 mM
EDTA. The mixture was heated for 5 min at 95 C and cooled
slowly to 25 C. The following oligonucleotides were prepared
to be used as cold NF-kB speciﬁc competition probe: 5
0
-AG-
TTGAGGGGACTTTCCCAGGCTTTTT-3
0
and 3
0
-TTTTTT-
CAACTC CCCTGAAAGGGTCCG-5
0
. The oligonucleotides
used as cold NF-kB nonspeciﬁc competition probe were: 5
0
-
AGTTGAGATTACTTTCACCAGGCTTTTT-3
0
and 3
0
-TTT-
TTTCAACTCTAATGAAAGTGTCCG-5
0
. The competitor
DNAs were synthesized with ﬁve protruding bases at each
3
0
end for protection from ExoIII digestion. The duplex
competitor DNAs were prepared in a manner similar to the
FRET probes.
DNA-binding proteins
Puriﬁed NF-kB p50 (rhNF-kB p50) and SP1 (rhSP1) were
purchased from Promega (Madison, WI). Human recombinant
NF-kB p50 was expressed in bacteria from a human cDNA
derived from the full-length p105. p50, a processed product of
its p105 precursor, is described as the ﬁrst DNA-binding sub-
unit of the NF-kB transcription factor. The SP1 recombinant
protein was expressed in a human baculovirus cDNA clone
in Sf9 cells. Puriﬁed p53 was purchased from ProteinOne
(College Park, MD). The wild-type p53 (393 amino acids)
was expressed in a baculovirus system and puriﬁed by an
afﬁnity column in combination with fast performance liquid
chromatography. The TNF-a-induced HeLa cell nuclear
extractwaspreparedusingaNuclearExtractKit(ActiveMotif,
Carlsbad, CA). The HeLa cell was cultivated and incubated
with or without TNF-a (R&D System, Minneapolis, MN;
20 ng/ml) for 30 min. The nuclear extract was collected
according to the manufacturer’s instructions and the protein
content was determined using a Bradford-based assay. The
activity of NF-kB p50 in the TNF-a-induced HeLa cell
nuclear extract was conﬁrmed by electrophoretic mobility
shift assay (EMSA) and super shift assay with a DIG-labeled
oligonucleotide (5
0
-AGTTGAGGGGACTTTCCCAGGC-3
0
)
(upper strand) and NF-kB (p50) antibody (Abcam,
Cambridge, UK) using a DIG Gel Shift Kit (Roche Molecular
Biochemicals, Mannheim, Germany). EMSA was performed
by incubating 10 mg of the HeLa cell nuclear extract in a 9 ml
bindingreactionmixturecontaining10mMTris–HCl(pH7.5),
50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 3 mM MgCl2,
0.05 mg/ml poly (dI-dC) and 10% (v/v) glycerol at 37 C for
10 min. The binding reaction mixture for the super shift assay
containing 1 ml of the non-diluted antibody of NF-kB (p50)
(Abcam, Cambridge, UK) was added to 1 ml of DIG-labeled
double-stranded oligonucleotide and was incubated at 37 C
for 20 min, followed by the addition of 1 ml of the gel loading
10· buffer (250 mM Tris–HCl, pH 7.5, 40% glycerol) at room
temperature. This mixture was then loaded on a pre-run 4%
polyacrylamide gel and run at 10 C in 0.5· TBE buffer at
350 V until the bromophenol blue dye was three-fourth of the
waydownthegel.Afterelectrophoresis,theDIG-labeledDNA
was electroblotted on the positively-charged nylon membrane
(Roche Molecular Biochemicals, Mannheim, Germany). The
blotted nylon membrane was ﬁxed by baking at 120 C for
15 min and the chemiluminescent detection was performed
according to the manufacturer’s instructions.
Fluorescence spectroscopy
All ﬂuorescence measurements were carried out at 25 Ci n
200 ml quartz cuvettes using an LS 55 spectroﬂuorometer
(PerkinElmer, Boston, MA). Spectra for single-color and two-
color detection experiments with puriﬁed recombinant pro-
teins were obtained using the DNA-binding buffer containing
10 mM Tris–HCl (pH 7.5), 50 mM NaCl, 0.5 mM EDTA,
0.5 mM DTT, 3 mM MgCl2, 0.05 mg/ml poly (dI-dC) (Roche,
Basel, Switzerland), 10% v/v glycerol, 0.5 mg/ml BSA and
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pre-incubated with DNA-binding buffer at 37 C for 10 min.
The FRET probe was then added and incubated at the same
temperature for further 20 min. At the end of the DNA–
protein-binding reaction, a sufﬁcient amount of ExoIII was
added and kept for 5min at 37 C. About 200 U of ExoIII
(MBI Fermentas, Hanover, MD) was used for all the FRET
probes of 25 nM concentration. EDTA was added to a ﬁnal
concentration of 20 mM to terminate the ExoIII reaction,
and the reaction mixture was immediately subjected to ﬂuore-
scence measurement.
For single-color detection of the target transcription factor
NF-kB in the HeLa cell nuclear extract, the nuclear extract
stimulated with or without TNF-a was pre-incubated in the
binding buffer containing 10 mM Tris–HCl (pH 7.5), 50 mM
NaCl,0.5mMEDTA,0.5mMDTT,3mMMgCl2,0.05mg/ml
poly (dI-dC), 10% v/v glycerol, 2 mM sodium phosphate,
pH 7.0, 20 ng/ml HaeIII-cut E.coli DNA and 25 ng/mlo f
yeast tRNA at 37 C for 10 min. The NF-kB probe was then
added and incubated at the same temperature for a further
20 min. After the binding step, ExoIII was added and the
probe was allowed to digest at 37 C for 5 min. The reaction
was terminated by the addition of EDTA to a ﬁnal concen-
tration of 20 mM. The assays of nuclear extract included an
additional ExoIII-negative control with nuclear extract, which
was used to detect any destruction of the FRET probe by
endogenous nuclease. The reaction mixture was immediately
subjected to ﬂuorescence measurement.
FRET analysis
In the FRET analysis, the following formula was used:
Relative FRET =  (Fe   Fs)/(Fe   Fn), where Fe was the
ﬂuorescence signal intensity of the free FRET probe digested
by ExoIII, Fs was the ﬂuorescence signal intensity of the
FRET probe bound by protein and digested by ExoIII, and
Fn was the ﬂuorescence signal intensity of the FRET probe not
digested by ExoIII. Fe was subtracted from Fs as background.
As a result, the relative FRET signal of the ExoIII-negative
control (Fn), the ExoIII-positive control (Fe) and the detected
samples (Fs) was 1, 0, and 0–1, respectively.
RESULTS
Mechanism
Figure 1 illustrates the general design of the FRET probe and
the mechanism of detection of the sequence-speciﬁc DNA-
binding proteins by our assay. The linear duplex DNA FRET
probeconsistsoftworeversecomplementaryoligonucleotides,
one was labeled with a ﬂuorochrome as donor and the other
was labeled with a ﬂuorochrome as acceptor. The donor and
acceptor ﬂuorochromes were brought into close proximity by
the annealing of the two oligonucleotides, resulting in a high
FRET probe signal. For protein detection, the FRET probe
harbors one complete protein-binding site at both sides of the
FRET pair. In essence, the detection of DNA-binding proteins
with the FRET probe is a special ExoIII protection assay. In
this assay, if a target protein is present, the protein will bind to
two protein-binding sites of the FRET probe and produce a
physical hindrance to ExoIII, which protects the FRET pair
from digestion by ExoIII and results in a high FRET signal.
On the contrary, in the absence of the target protein, the naked
FRET probe will be degraded by ExoIII and the close prox-
imity of the FRET pair is thus destroyed, resulting in a low
FRET signal.
Itshouldbe notedthat thefollowingaspectsareimportantin
the preparation of the FRET probe. First, there should be
enough ﬂanking sequences on both sides of the two protein-
binding sites, as the DNA sequence covered by protein in the
DNA–protein complex is often larger than the protein-binding
site. Second, the FRET pair should be sufﬁciently far away
from both the protein-binding sites, lest it results in steric
hindrance to protein binding. Third, ExoIII preferentially
binds to a free 3
0
hydroxyl on the double-stranded DNA and
then cleaves inward in a semiprocessive fashion. The FRET
probe should therefore have a recessed or blunt 3
0
hydroxyl
group at both ends. The protruded 3
0
end larger than four bases
is not permitted in the FRET probe.
Feasibility
Toverifyourassay(Figure1)experimentally,weﬁrstprepared
a FRET probe for detecting NF-kB, a transcription factor that
bindstotheconsensusDNAofGGGACTTTCCinasequence-
speciﬁc manner(6).TheNF-kBprobeconsistedoftworeverse
complementary oligonucleotides. One oligonucleotide was
labeled with FAM as donor and the other was labeled with
Dabcylasacceptor.TheFAMandDabcylwereintroducedinto
oligonucleotides using dT-ﬂuorescein and dT-Dabcyl. Two
complete 10 bp NF-kB-binding sites of GGGACTTTCC were
contained in the NF-kB probe, which ﬂanked the FRET pair of
FAM/Dabcyl. A 10 and 8 bp sequence was, respectively,
stuffedbetweenthe two NF-kB-binding sites and a FRET pair.
TheFAMandDabcylwerebroughtintocloseproximitybythe
annealing of two oligonucleotides to obtain a high FRET
signal (Figure 2A, curve 2). Once ExoIII was added into the
NF-kB probe solution, dT-FAM and dT-Dabcyl were released
as mononucleotides from the NF-kB probe by ExoIII diges-
tion. The close proximity of the FRET pair of FAM/Dabcyl
was thus destroyed, resulting in a low FRET signal of the
NF-kB probe (Figure 2A, curve 1). The ExoIII digestion of
the NF-kB probe was also conﬁrmed by gel electrophoresis
and UV transilluminator imaging (inset of Figure 2A).
Figure 1. Schemes of ExoIII protection assay with the FRET probe. PBS,
protein-bindingsitesofthe FRETprobe.Thesolid andopenflags onthe FRET
probe represent the fluorescence donor and acceptor. The ellipse represents
DNA-binding protein.
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longer than the time required for the ExoIII reaction, ExoIII
can wait until the protein falls off its site and passes through it
infootprinting(19).Toavoidproducingafalsenegativeresult,
we assumed complete ExoIII digestion of the NF-kB probe in
short time to eliminate the ExoIII activity. We investigated the
efﬁciency of ExoIII digestion of the NF-kB probe by per-
forming a real-time PCR. In the experiment, the NF-kB probe
solution was taken in the PCR tube, followed by addition of
the ExoIII solution in the lids of PCR tubes. Under a simple
PCR program of incubation at 37 C and detection at 470 nm
on RotorGene 2000 (Corbett Research, Australia), the ExoIII
solutions were centrifuged into the NF-kB probe solutions,
and the dynamics of ExoIII digestion of the NF-kB probes
were therefore recorded (Figure 2C). It was demonstrated that
the ExoIII digestion was completed in 5 min at the proper ratio
of DNA and FRET probe. Before performing other experi-
ments, the ratio of DNA to ExoIII was optimized by carrying
out a real-time PCR and gel electrophoresis.
Based on the principle of DNA footprinting with ExoIII, we
designed our assay for the detection of DNA-binding proteins.
We assumed that the binding of target protein to the FRET
probe could protect the FRET pair from being degraded by
ExoIII. Figure 2B and its insets show that, as predicted, in the
presence of NF-kB p50, a portion of the NF-kB probe bound
by NF-kB p50 was protected from ExoIII digestion, resulting
in the increase of the FRET signal when compared with the
negative control containing no p50 protein. The binding of p50
to the NF-kB probe and ExoIII digestion were also conﬁrmed
bygelelectrophoresisandUVtransilluminator imaging(insets
of Figure 2B). The dynamics of ExoIII digestion of the p50-
bound probe was monitored by real-time PCR (Figure 2C),
which revealed that the ExoIII digestion of the solutions with
and without p50 could reach equilibrium at the same time.
After 5 min of digestion, ExoIII activity was completely
terminated by adding EDTA. The EDTA-terminated reaction
was immediately analyzed using a spectroﬂuorometer. All
these data veriﬁed the design of our assay.
Specificity and applicability
In addition, we investigated the speciﬁcity of our assay. For
performing competitive assays, two non-labeled competitor
duplex DNAs were prepared, one containing a consensus
NF-kB binding site of GGGACTTTCC as a speciﬁc compet-
itor, and the other not containing any NF-kB binding site as
the non-speciﬁc competitor. The results of competition assays
are shown in Figure 3. It was demonstrated that the speciﬁc
competitor DNA reversed the FRET signal produced by p50
(Figure 3A and C), whereas the nonspeciﬁc competitor DNA
had no effect (Figure 3B and C). These results conﬁrmed the
speciﬁcity of our assay. Italsosuggests that this method can be
used for the rapid assessment of the relative binding afﬁnity of
the protein to various DNAs.
We next investigated the possibility of the assay for the
quantitative detection of the DNA-binding proteins. By adding
increasing amounts of NF-kB p50 to a series of same molar
NF-kB probes and then performing simultaneous ExoIII
digestion, we found that the FRET signal of the NF-kB probe
increased with the increase in NF-kB p50 (Figure 4A and B).
This result implies that under optimized experimental condi-
tions, it is possible to employ the assay to quantify DNA-
binding proteins. We performed similar quantiﬁcation assays
with two other sequence-speciﬁc DNA-binding proteins, the
human transcription factor SP1 (20,21) and p53 (22). For both
proteins, we observed an increase in the FRET signal with the
increase in protein concentration (Figure 4C–F). These data
provide additional evidence for the applicability of the assay.
The assay can be generally applied to the detection of the fast-
growing numbers of the known DNA-binding proteins.
Nuclear extracts detection
ExoIII was demonstrated to be capable of detecting speciﬁc
DNA–protein interactions in crude extracts in the DNA
protection assay (23–28). It prompted us to investigate the
applicability of our assay to cell nuclear extracts. However,
interference may arise in the assay due to the endogenous
Figure 2. ExoIII digestion of the FRET probe. (A) Emission spectra of free NF-kB probe digested by ExoIII. Curve 1, the 25 nM NF-kB probe digested by ExoIII
(ExoIII-positive control); Curve 2, the 25 nM NF-kB probe not digested by ExoIII (ExoIII-negative control). (B) Emission spectra of p50-bound NF-kB probe
digested by ExoIII. Insets are gel electrophoresis and UV transilluminator images. (C) Dynamics of ExoIII digestion of NF-kB probes. In (B) and (C), curve 1,
theExoIII-positivecontrolof25nMNF-kBprobe;curve2,the25nMNF-kBprobeboundby15nMp50anddigestedbyExoIII;curve3,theExoIII-negativecontrol
of the 25 nM NF-kB probe.
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problem,sodium phosphate and carrier nucleic acids including
poly(dI-dC), HaeIII-cut E.coli DNA and yeast tRNA were
included in our assay for suppressing endogenous nuclease
activities in the crude extracts (24,26). For the detection of
the target transcription factor NF-kB in the HeLa cell nuclear
extract, the HeLa cell was induced with TNF-a to increase the
amount of NF-kB in the HeLa cell nuclear extract (29). The
NF-kB p50 activity of the harvested nuclear extracts was
conﬁrmed by EMSA and super shift assay to provide a nuclear
extract sample for NF-kB detection by our assay. The NF-kB
proteininthe HeLa cellnuclear extract was detectedby adding
increasing amounts of nuclear extracts to a series of NF-kB
probes of the same molar concentration. As shown in Figure 5,
the relative FRET increased with an increase in the amount of
extract (Figure 5A and B). The competition assays with cold
speciﬁc and nonspeciﬁc probes demonstrated that the extract-
dependent variation of the FRET signal was NF-kB-speciﬁc
(Figure 5C). The ExoIII-negative control with the nuclear
extract revealed that the addition of sodium phosphate and
carrier nucleic acids suppressed the possible endogenous
nucleaseactivitywhichmaydestroytheFRETprobe(sample7
in Figure 5A–C). These data indicate that ExoIII protection
assay with the FRET probe can be used to detect proteins in
crude extracts.
Simultaneous detection of two proteins
To demonstrate that our assay can be used for multicolor
detection, we prepared a JOE-labeled p53 probe for carrying
out the simultaneous, independent two-color detection of p50
and p53 proteins in a single assay. The probe solution used
in this experiment consisted of equal amounts of the FAM-
labeled p50 probe and the JOE-labeled p53 probe. Both probes
contained Dabcyl as acceptor. The maximum excitation wave-
lengthsof FAM and JOE are 494 nm and 520 nm, respectively.
The maximum emission wavelengths of FAM and JOE are
520 nm and 548 nm, respectively. Thus, excitation at 494 nm
provides the ﬂuorescence signal only for the NF-kB probe at
the maximum wavelength of 520 nm, and excitation at 520 nm
provides the ﬂuorescence signal only for the p53 probe at the
maximum wavelength of 548 nm. We mixed equal amounts of
the two probes and aliquots were distributed into ﬁve tubes.
In two tubes (A and B), no protein was added, in two other
tubes p50 (C) and p53 (D), respectively, were added and in the
last tube (E), both p50 and p53 were added. After the binding
reaction, same units of ExoIII were added into tubes B, C, D
and E. Addition of p50 to the double-probe solution resulted in
an increase in the FRET signal at the wavelength of 520 nm
(Figure 6A), whereas addition of p53 resulted in an increase
in the FRET signal at a wavelength of 548 nm (Figure 6B),
and addition of both the proteins resulted in increases in the
FRET signal at both wavelengths of 520 nm and 548 nm
(Figure 6A–C). These data provide evidence for the feasibility
oftwo-colordetectionoftwodifferentproteinssimultaneously
by our assay. If multiple ﬂuorochromes are employed in the
assay, it should be possible to detect multiple proteins in high-
throughput format.
DISCUSSION
FRET (15) provides a powerful technique for the detection of
biologicalinteractions(13,30–33).Ithasalreadybeen success-
fully used in the detection of DNA–protein interactions
(13,14,34). In the detection of DNA–protein interactions
using FRET technology, the method by which the DNA or
protein is labeled is very important. In general, two labeling
strategies were adopted in previous studies. In the ﬁrst strat-
egy, the DNA is labeled with one ﬂuorochrome and the protein
with another ﬂuorochrome; FRET is produced by the proxim-
ity between DNA and protein in the protein–DNA complex
(13,35). In the other strategy, known as the molecular beacon
assay, the DNA is labeled with two ﬂuorochromes, each
appearing in one duplex DNA of the two half sites of a
DNA-binding protein; FRET is produced by the protein-
driven annealing of two half sites (14,35). In the ﬁrst FRET
strategy, detection of DNA-binding proteins depends on FRET
between the two ﬂuorochromes in a DNA–protein complex
(34). The ﬁrst limitation of this approach is that both the DNA
Figure 3. Specificity of protein detection. (A) Emission spectra of the 25 nM NF-kB probes in the presence of 20 nM NF-kB p50 and increasing amounts of cold
specific probe. (B) Emission spectra of the 25 nM NF-kB FRET probes in the presence of 20 nM NF-kB p50 and increasing amounts of cold nonspecific probe.
(C)RelativeFRETofthecompetitionassay.Thefinalconcentrationsofthecompetitorprobewere0nM(6and60),10nM(5and50),20nM(4and40),40nM(3and
30) and 80 nM (2 and 20). ExoIII-positive and ExoIII-negative controls of the 25 nM NF-kB probe were (1 and 10) and (7 and 70), respectively.
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protein labeling is not always easy as it may affect the native
features of the protein. The second limitation is that large
proteins may increase the distance between the donor and the
acceptor in the protein–DNA complex; therefore, the FRET
signal may not be measurable. Finally, the optimum formation
of a protein–DNA complex often requires an excess of one
labeled component over the other, which does not ensure
a 1:1stoichiometry of ﬂuorescence donor and acceptor groups,
and thus produce difﬁculties in the detection of the ﬂuore-
scence signal. In the second FRET strategy using molecular
beacons, detection of the DNA-binding protein relies on the
protein-driven FRET between the two ﬂuorochromes in the
complex of the protein and the two DNA half sites (14). The
assay does not require labeling of the protein and circumvents
the deﬁciencies of the ﬁrst FRET strategy. It develops a sim-
ple, rapid, homogeneous and high-throughput ﬂuorescence
assay for the detection and quantiﬁcation of DNA-binding
proteins. However, the molecular beacon assay may be limited
by some difﬁculties. First, it is difﬁcult to design molecular
beacons for those proteins with small binding sites. Second,
it may be not easy to prepare the optimal DNA–protein bind-
ing buffer which keeps DNA half sites apart without the
protein but provides the optimal condition for DNA–protein
Figure 4. Protein concentration dependence of the FRET signal. (A) Emissionspectra of the 25 nM NF-kB probes in the presence of increasing amounts of NF-kB
p50. (B) NF-kB p50 concentration–dependent relative FRET.(C) Emissionspectra of the 25 nM SP1 probes in the presence of increasing amountsof SP1. (D) SP1
concentration–dependent relative FRET. (E) Emission spectra of the 25 nM p53 probes in the presence of increasing amounts of p53. (F) p53 concentration–
dependent relative FRET. The final concentration of proteins were 0 nM (1), 5 nM (2), 10 nM (3), 15 nM (4), 20 nM (5), 30 nM (6) and 50 nM (7). ExoIII-negative
control of the 25 nM FRET probe was (8).
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binding site may interfere with the protein–DNA interaction.
In comparison with the two existing FRET-based methods,
our assay provides a more easy and simple approach for the
detection of DNA-binding proteins. In our assay, the FRET
probe was employed as a substitute of a radiolabeled probe
in a common ExoIII protection assay. This assay has several
advantages. First, the design, preparation and application of
the FRET probe are easy and ﬂexible. This assay does not
require labeling of the protein, which helps to preserve the
natural features of the target protein and allows the detection
of crude cell extracts. The labeling of the FRET probe with a
ﬂuorescence donor and acceptor is very simple. The donor and
acceptor can be easily designed to be in close proximity in the
FRET probe, and they are still sufﬁciently separated from each
other after ExoIII digestion, resulting in a large dynamic range
of the signal change before and after ExoIII digestion. The
dynamic range and sensitivity can be further optimized by
adding more than one FRET pairs in the FRET probe. The
FRET pair is designed to be sufﬁciently separated from the
protein-binding sites to prevent possible steric hindrance from
the FRET pair from exerting its inﬂuence on the formation of
the protein–DNA complex. The FRET probe consisting of
complete protein-binding sites is helpful for natural and
optimal interaction between DNA and protein. For optimal
detection of proteins with small binding sites, more than
one protein-binding site on both sides of FRET pairs can be
placed in the FRET probe. The same protein-binding sites on
both sides of the FRET pair can be changed into two different
binding sites for two different proteins. This type of FRET
probe can be used to investigate whether the two proteins are
expressed coordinately in cells and also to study their rela-
tionship. If multiple FRET probes are labeled with different
FRET pairs, the assay allows detection of multiple proteins
simultaneously. Besides using Dabcyl as a black acceptor,
the acceptor can be another ﬂuorescein molecule with an
Figure5.Nuclearextractdetectionbytheassay.(A)Emissionspectraof25nMNF-kBprobesinthepresenceofincreasingamountsoftheTNF-a-inducedHeLacell
nuclear extract. The finalconcentrationsof extract were 0 mg/ml (1), 0.05mg/ml (2), 0.1 mg/ml (3), 0.2 mg/ml (4), 0.4 mg/ml (5)and 0.8 mg/ml (6). The ExoIII-negative
control of the 25 nM NF-kB probe was (8). An additional ExoIII-negative control which contained 0.8 mg/ml extract was (7). (B) Nuclear extract concentration
dependence of the FRET signal. (C) Relative FRET signal of the competition assay. The assay solutions contained 25 nM NF-kB probes, the 0.4 mg/ml TNF-a-
induced HeLa cell nuclear extract and different concentrations of the cold specific (2–6) and nonspecific (20–60) competitor probes. The final concentration of
competitorprobeswere0nM(6and60),10nM(5and50),20nM(4and40),40nM(3and30)and80nM(2and20).ExoIII-positiveand-negativecontrolsofthe25nM
NF-kB probe were (1 and 10) and (7 and 70), respectively.
Figure 6. Simultaneous detection of two proteins. (A) Emission spectra with excitation at 480 nm (absorption wavelength of FAM). (B) Emission spectra with
excitation at 520 nm (absorption wavelength of JOE). (C) Relative FRET signal of the assay. 1: no p50, no p53; 2: 15 nM p50, no p53; 3: no p50, 15 nM p53;
4: 15 nM p50, 15 nM p53. The concentrations of the NF-kB and p53 FRET probes used are 25 nM.
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of the donor ﬂuorescein. In this case, protein detection can be
accomplished by measuring either the decrease in the donor
signal or the increase in the acceptor signal, or by assessing the
ratio between the two signals (14). Other proximity-based
luminescence signals can be ﬂexibly used in place of FRET
as the detection signal (11,36–42). Second, it is easy to estab-
lish the optimal conditions for DNA–protein binding and
ExoIII digestion. In our assay, since the state of the DNA
probes is not as important as in the molecular beacon assay,
and the ExoIII activity is rather stable over a wide range of
ionic strengths, the DNA-binding buffer is easy to prepare for
obtaining the optimum yield of speciﬁc protein–DNA com-
plexes. We found that the optimized DNA-binding buffer was
also suitable for the ExoIII reaction. Thus, there is no need to
add any other component besides ExoIII for performing the
protection assay. The ExoIII activity is high at 37 C, the most
common reaction temperature for DNA–protein interaction.
Finally, the procedure of our assay is very simple and time-
saving. The protocol includes three steps, including DNA–
protein binding, ExoIII digestion and stopping. The whole
assay can be completed in 30 min. As a result, our assay pro-
vides an easy, simple, sensitive, ﬂexible and high-throughput
technique for the detection of DNA-binding proteins.
ExoIII is a 28 kDa monomeric enzyme with 3
0
to 5
0
exo-
nuclease activity (43). It is used in the construction of nested
unidirectional deletions of DNA fragments (44), generation of
a single-stranded template for dideoxy sequencing of DNA
(45), site-directed mutagenesis (46), cloning of PCR products
(47) and DNA footprinting assays (10,24,48–50). In DNA
footprinting assays, after a protein speciﬁcally binds to a
DNA fragment containing its recognition site, ExoIII is used
to remove mononucleotides from both DNA strands in a pro-
cessive fashion, beginning from the 3
0
ends. The speciﬁcally
bound protein blocks the action of ExoIII and leaves double-
stranded DNA only in the region bound by the protein, but
any free-DNA is fully digested. The successful use of ExoIII
in DNA footprinting assays depends on several factors. First,
the half-life of the protein–DNA complex is longer than the
time required for the ExoIII reaction and, in most cases, the
half-life of the complex is not changed by the ExoIII digestion
of the DNA (24,51,52). Second, ExoIII activity is rather stable
over a wide range of ionic strengths between 0 and 100 mM
NaCl (or KCl) (19). However, other common nucleases with
exonuclease activity of Bal31 (53) require very high ionic
strengths of 600 mM NaCl; it is therefore not applicable in
our assay. Finally, ExoIII possesses high activity, releasing
mononucleotides as many as 420 bases per minute at 37 C
(DatasheetofexonucleaseIII,MBIFermentas,Hanover,MD).
These features of ExoIII make it easily adaptable to our assay.
Another important advantage of ExoIII is that it can be used to
detect speciﬁc DNA–protein interactions in crude extracts
(23–27), which makes ExoIII more suitable for the clinical
sample assay, such as tissue extracts. In footprinting, ExoIII
footprints are slightly smaller than DNase I footprints. For
example, ExoIII generates a 21 bp footprint for GAL4,
whereas the footprint of DNase I is 27 bp (50). The shorter
footprint of ExoIII is preferable for the FRET probe synthesis
at lower cost in our assay. The major disadvantage of ExoIII is
that it sometimes nibbles into a protein-bound DNA segment
for proteins with lower binding afﬁnity, and even displaces
some DNA-binding proteins from DNA as the GAGA factor
(19). To avoid this problem, more than one protein-binding
site can be harbored on both the sides of FRET pairs, or a
selective natural or artiﬁcial binding site with high binding
afﬁnity can be used in our assay. In total, ExoIII is a very
suitable nuclease for our assay.
CONCLUSIONS
We have described a novel method to detect sequence-speciﬁc
DNA-binding proteins. We named this method as ExoIII
protection assay with FRET probe, which combines FRET
technology with an ExoIII protection assay, to develop a
simple, sensitive and high-throughput method for detecting
sequence-speciﬁc DNA-bindingproteins, such as transcription
factors. We employed this method to successfully detect three
different transcription factors, NF-kB, SP1 and p53, in quant-
itative and speciﬁc formats. The results also revealed that the
assay could be used to detect DNA-binding proteins in crude
cell nuclear extracts. Therefore, the assay has wide potential
application in research and biomedicine. In research, the assay
provides a convenient tool for detecting the presence and
monitoring the DNA-binding activity of the fast-growing
numbers of DNA-binding proteins. In biomedicine, the assay
can be applied to identify the presence or the activity of a
DNA-binding protein in disease samples (tissue extracts) in
medical diagnosis, and to screen potential drugs targeted at a
DNA-binding protein in medicine development.
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